CODX vs UNH

Co-Diagnostics (CODX) remains a highly speculative, high-risk investment, now facing severe financial headwinds. The company reported a significant 84.6% YoY revenue decline in FY2025 and a 60% reduction in cash, indicating rapid cash burn. Despite these challenges, CODX continues its strategic pivot, showcasing its Co-Dx PCR platform and expanding international relationships, which aligns with pr...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...